Extensions

To provide a comprehensive analysis of US Patent 11,344,552 regarding patent term adjustments (PTA), patent term extensions (PTE), continuation/divisional applications, related family members, and projected expiration date, direct access to the USPTO's Patent Center or PAIR (Patent Application Information Retrieval) system is typically required. Public Google searches provide some information, but a direct USPTO database search would yield the most precise and complete details.

Based on the available information:

Patent Term Adjustments (PTA)

Patent Term Adjustment (PTA) is additional time added to the term of a U.S. patent to compensate for delays caused by the USPTO during the prosecution of a utility or plant patent application. This adjustment is typically calculated after the patent is granted. Factors such as delays in issuing office actions, responding to applicant replies, or issuing the patent can contribute to PTA.

The provided information does not explicitly state the specific PTA granted for US Patent 11,344,552. To determine the exact PTA, one would need to access the official patent file in the USPTO's Patent Center or PAIR system.

Patent Term Extensions (PTE)

Patent Term Extension (PTE) is a statutory remedy, primarily under 35 U.S.C. § 156, designed to restore patent term lost due to the lengthy regulatory review process for certain products, particularly pharmaceuticals and medical devices, by agencies like the FDA.

The patent text for US 11,344,552 mentions that MM-398 (liposomal irinotecan, marketed as ONIVYDE®) is an FDA-approved product. Given that the patent covers methods for treating metastatic pancreatic cancer using this drug combination, it is a candidate for PTE. However, the available information does not specify if a PTE was applied for or granted for US Patent 11,344,552. An application for PTE must be submitted to the USPTO within 60 days of regulatory agency approval of the commercial marketing application. Only one patent can be extended for a regulatory review period for any product, and the extension is limited to a maximum of five years, and the total post-approval patent life cannot exceed 14 years from the date of FDA approval.

Continuation and Divisional Applications

• Continuation Applications: US Patent 11,344,552 is explicitly stated to be a "continuation of U.S. application Ser. No. 15/241,106, filed Aug. 19, 2016".
• Divisional Applications: The provided information does not explicitly mention any divisional applications directly stemming from US Patent 11,344,552 or its direct parent.

Related Family Members

The patent states it claims the benefit of priority to several U.S. Provisional Application Nos.:

• 62/208,209, filed Aug. 21, 2015
• 62/216,736, filed Sep. 10, 2015
• 62/273,244, filed Dec. 30, 2015
• 62/281,473, filed Jan. 21, 2016
• 62/302,341, filed Mar. 2, 2016
• 62/323,245, filed Apr. 15, 2016
• 62/343,313, filed May 31, 2016

It is also a continuation of U.S. Application Ser. No. 15/241,106, filed August 19, 2016.

Additionally, the "Other versions" section of the Google Patents page lists US20180078556A1, which is a published application related to this patent. Other priority claims are mentioned, including US17/711,500 (priority to 2022-04-01), US18/676,591 (priority to 2024-05-29), and US19/188,672 (priority to 2025-04-24). These suggest further related applications, possibly continuations or divisionals, that have been filed more recently.

Projected Expiration Date

The general rule for utility patents is that the term ends 20 years from the filing date of the earliest non-provisional application for which a benefit is claimed under 35 U.S.C. § 120, 121, or 365(c). This patent claims priority from a U.S. non-provisional application filed on August 19, 2016 (U.S. application Ser. No. 15/241,106), which itself claims priority to several provisional applications, with the earliest priority date being August 21, 2015.

Therefore, the unadjusted statutory expiration date would be 20 years from the earliest non-provisional filing date (August 19, 2016), which would be August 19, 2036.

This date would then be adjusted by any Patent Term Adjustments (PTA) for USPTO delays and potentially extended by any Patent Term Extensions (PTE) due to regulatory review delays. As noted above, the specific PTA or PTE amounts are not publicly available in the provided text. The anticipated expiration date listed on Google Patents is also 2036-08-19.